Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Lung: Adenocarcinoma with t(6;12)(q22;q14.1) LRIG3/ROS1

Written2014-02Kana Sakamoto, Yuki Togashi, Kengo Takeuchi
Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

(Note : for Links provided by Atlas : click)


Atlas_Id 6496
Phylum Lung, Heart, Skin, Other::Adenocarcinoma
WHO/OMS Classification Lung, Heart, Skin, Other

Clinics and Pathology

Disease Lung adenocarcinoma
Epidemiology ROS1 translocations are found in 0.9 to 1.7% of non small cell lung carcinomas and the majority of the cases are adenocarcinoma (Bergethon et al., 2012; Davies et al., 2012; Takeuchi et al., 2012). Multiple fusion partners have been identified and LRIG3 is one of them. As for LRIG3-ROS1, only one case, a 57-year-old Japanese male patient, has been reported to date (Takeuchi et al., 2012).
Clinics The patient had a 5 pack year of smoking history and was diagnosed as having stage 1A lung adenocarcinoma.
Pathology This case showed moderately differentiated micropapillary pattern. A mucinous cribriform pattern which is frequently seen in cancers with kinase fusions was not found. This case was negative for EGFR and KRAS mutations as with the most cases harboring ROS1 gene fusions.
Treatment The primary tumor was surgically removed and the patient received post-operative chemotherapy with UFT. Although not administered in this case, Crizotinib and other ALK inhibitors have been reported to be effective in lung cancers with ROS1 translocations (Bergethon et al., 2012; Shaw et al., 2012).
Prognosis With 5 years of follow-up, the patient was alive without relapse.

Genes involved and Proteins

Gene NameLRIG3 (Leucine-Rich Repeats And Immunoglobulin-Like Domains 3)
Location 12q14.1
Dna / Rna Leucine-Rich Repeats And Immunoglobulin-Like Domains Protein 3.

Gene NameROS1 (ROS proto-oncogene 1 , receptor tyrosine kinase)
Location 6q22.1
Dna / Rna C-Ros Oncogene 1, Receptor Tyrosine Kinase.

Result of the chromosomal anomaly

Hybrid Gene
Transcript LRIG3-ROS1 fusion transcript was detected.
Detection A 218 bp cDNA fragment harboring the fusion point can be detected with LRIG3 forward primer (5'-ACACAGATGAGACCAACTTGC-3') and ROS1 reverse primer (5'-CACTGTCACCCCTTCCTTG-3').
Fusion Protein
Description A. The schematic structure of LRIG3, ROS1, and LRIG3-ROS1 proteins and the cDNA sequence around the fusion point: Exon 16 of LRIG3 fused to exon 35 of ROS1. The break point of ROS1 allows the resulting fusion protein to retain the kinase domain (red). LRIG3 contains a transmembrane domain (orange). B: RT-PCR confirmation of LRIG3-ROS1 fusion: Lane M and N represent the size standard (20-bp ladder) and the non-template control, respectively. C. Fusion FISH analysis: A fusion signal (yellow) was observed in consequence of the fusion of LRIG3 (red) and ROS1 (green).
Description The fusion protein encompasses the constitutive activation of ROS1 tyrosine kinase. However, the mechanism of it is largely unknown. The role of LRIG3 here has not been clarified. LRIG3 protein does not contain a coiled-coil domain as in the case with most of the other ROS1 fusion partners (Takeuchi et al., 2012).
In respect of the downstream signaling, several growth and survival signaling pathways which are common to other receptor tyrosine kinases have been shown to be involved. These include PI3K/AKT, JAK/STAT3, RAS/MAPK/ERK, VAV3, and SHP-1 and SHP-2 pathways (Chin et al., 2012; Davies and Doebele, 2013).
Oncogenesis The oncogenicity of LRIG3-ROS1 fusion was proven in a focus formation assay and a nude mouse tumorigenicity assay (Takeuchi et al., 2012).


ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ.
J Clin Oncol. 2012 Mar 10;30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3.
PMID 22215748
Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
Chin LP, Soo RA, Soong R, Ou SH.
J Thorac Oncol. 2012 Nov;7(11):1625-30. doi: 10.1097/JTO.0b013e31826baf83. (REVIEW)
PMID 23070242
Molecular pathways: ROS1 fusion proteins in cancer.
Davies KD, Doebele RC.
Clin Cancer Res. 2013 Aug 1;19(15):4040-5. doi: 10.1158/1078-0432.CCR-12-2851. Epub 2013 May 29. (REVIEW)
PMID 23719267
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC.
Clin Cancer Res. 2012 Sep 1;18(17):4570-9. doi: 10.1158/1078-0432.CCR-12-0550. Epub 2012 Aug 23.
PMID 22919003
Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.
Shaw AT, Camidge DR, Engelman JA, Solomon BJ, Kwak EL, Clark JW, Salgia R, Shapiro G, Bang YJ, Tan W, Tye L, Wilner KD, Stephenson P, Varella-Garcia M, Bergethon K, Iafrate AJ, Ou SHI.
J Clin Oncol 2012;30:(suppl; abstr 7508).
RET, ROS1 and ALK fusions in lung cancer.
Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y.
Nat Med. 2012 Feb 12;18(3):378-81. doi: 10.1038/nm.2658.
PMID 22327623


This paper should be referenced as such :
K Sakamoto, Y Togashi, K Takeuchi
Lung: t(6;12)(q22;q14.1) LRIG3/ROS1 in lung adenocarcinoma
Atlas Genet Cytogenet Oncol Haematol. 2014;18(9):688-690.
Free journal version : [ pdf ]   [ DOI ]
On line version :

Other genes implicated (Data extracted from papers in the Atlas) [ 1 ]

Genes LRIG3

Translocations implicated (Data extracted from papers in the Atlas)

 t(6;12)(q22;q14.1) LRIG3/ROS1

External links

Mitelman database t(6;12)(q22;q14.1) [CaseList]     t(6;12)(q22;q14.1) [Transloc - MCList]   LRIG3/ROS1 Fusion - MCList]
COSMIC[ LRIG3 ]   [ ROS1 ]
arrayMap arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
COSMIC_fusionLRIG3 (12q14.1) ROS1 (6q22.1)    [fusion1269] [fusion1270]
Mitelman databaseLRIG3/ROS1[MCList]    LRIG3 (12q14.1) ROS1 (6q22.1)   t(6;12)(q22;q14)
Disease databaseLung: Adenocarcinoma with t(6;12)(q22;q14.1) LRIG3/ROS1
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Dec 14 18:30:49 CET 2020

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us